Summit Therapeutics (NASDAQ: SMMT) is down about 3.12% in Tuesday trading (April 28, 2026) to roughly $21.44, extending a pullback that looks more like post-run digestion than a reaction to a fresh headline. A scan of recent company communications and widely circulated market news shows no new Summit press release or newly surfaced material SEC disclosure specifically timed to today’s move, pointing to technical trading and sentiment swings as the primary drivers.

The most plausible explanation is profit-taking and de-risking after a catalyst-heavy stretch in which investors have repeatedly repriced SMMT on ivonescimab milestones rather than on near-term revenue. Summit recently highlighted that multiple Phase III ivonescimab data sets in advanced NSCLC are slated for presentation at ELCC 2026, and the company has also disclosed that the FDA accepted its BLA with a PDUFA goal date of November 14, 2026—events that can fuel sharp upswings and equally sharp givebacks when incremental news is absent. In addition, SMMT’s elevated short interest can contribute to outsized day-to-day volatility as positioning shifts around biotech catalysts.

Near-term attention remains on upcoming ivonescimab clinical-data visibility (including ELCC 2026) and the regulatory path toward the November 14, 2026 PDUFA decision date. Traders will also watch whether the pullback stabilizes on normal volume versus accelerating on heavy volume, which would suggest a more fundamental repositioning rather than a routine reset.

Today’s decline looks like a headline-light pullback in a high-beta biotech name that has been trading primarily on ivonescimab expectations. Unless new clinical, regulatory, or financing news emerges, SMMT is likely to remain driven by catalyst timing, risk appetite, and positioning dynamics rather than company-specific developments on April 28.